Stay updated on BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page.

Latest updates to the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe page shows a new revision label, 'v3.4.2', replacing 'v3.4.1'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check15 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; this is a minor metadata page change and does not affect study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check37 days agoChange DetectedVersion updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.0%

- Check59 days agoChange DetectedThe page now lists study locations by state (Arkansas, California, Florida, Kentucky, Louisiana, Missouri, Nevada, New Jersey, Ohio, South Carolina, Texas) and shows an updated revision tag (v3.3.3). The HHS Vulnerability Disclosure link was removed.SummaryDifference1%

- Check88 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check95 days agoChange DetectedThe notice regarding government funding and operating status was removed from the page, a non-critical informational banner. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page.